Developing innovative therapies for those living with serious rare and ultrarare genetic diseases
Our approach has led to the delivery of multiple first-ever rare disease treatments at a faster speed than the industry average.
CRYSVITA®
Patients and healthcare providers, learn more at CRYSVITA.com
Read the U.S. Prescribing Information for CRYSVITA
UltraCare: Our program to help facilitate patient access to our medicines. Learn more at UltraCareSupport.com
DOJOLVI®
Patients and healthcare providers, learn more at DOJOLVI.com
Read the U.S. Prescribing Information, including the Patient Information Leaflet, for DOJOLVI
UltraCare: Our program to help facilitate patient access to our medicines. Learn more at UltraCareSupport.com
MEPSEVII®
Patients and healthcare providers, learn more at MEPSEVII.com
Read the U.S. Prescribing Information for MEPSEVII
UltraCare: Our program to help facilitate patient access to our medicines. Learn more at UltraCareSupport.com
Discover more about Ultragenyx:
Latest news
Get the latest information related to our company, our pipeline, and our medicines.
Visit the newsroom